Table 1 Baseline co-variates of patients with haematologic cancers, 1975-2016.
From: Changing causes of death in persons with haematological cancers 1975–2016
Baseline co-variates | N (%) | Total Follow-up time (years) | Deaths from all causes (%) | Deaths from non-cancer causes | |
|---|---|---|---|---|---|
No. of observed deaths (%) | SMR (95% CI) | ||||
All | 683,333 (100%) | 3,755,161 | 390,534 (100%) | 113,172 (100%) | 2.51 (2.49–2.52) |
Age | |||||
0–19 | 39,847 (6%) | 404,726 | 8616 (2%) | 1280 (1%) | 5.96 (5.64–6.30) |
20–39 | 70,378 (10%) | 634,977 | 23,146 (6%) | 6998 (6%) | 9.31 (9.09–9.53) |
40–59 | 175,767 (26%) | 1,182,981 | 78,393 (20%) | 19,885 (18%) | 4.45 (4.39–4.51) |
60–79 | 292,883 (43%) | 1,306,862 | 191,340 (49%) | 54,651 (48%) | 2.55 (2.53–2.57) |
80+ | 104,458 (15%) | 225,615 | 89,039 (23%) | 30,358 (27%) | 1.66 (1.64–1.68) |
Sex | |||||
Female | 305,627 (45%) | 1,722,851 | 172,502 (44%) | 47,833 (42%) | 2.44 (2.42–2.46) |
Male | 377,706 (55%) | 2,032,311 | 218,032 (56%) | 65,339 (58%) | 2.55 (2.53–2.57) |
Race | |||||
White | 567,502 (83%) | 3,187,711 | 329,103 (84%) | 95,587 (85%) | 2.40 (2.39–2.42) |
Black | 66,016 (10%) | 315,522 | 38,769 (10%) | 12,166 (11%) | 3.21 (3.15–3.26) |
Other | 49,815 (7%) | 251,928 | 22,662 (6%) | 5,419 (5%) | 3.41 (3.32–3.50) |
Year of diagnosis | |||||
1975–1989 | 89,574 (13%) | 708,262 | 80,674 (21%) | 23,170 (21%) | 3.08 (3.05–3.12) |
1990–1999 | 107,421 (16%) | 826,692 | 84,143 (22%) | 26,284 (23%) | 2.98 (2.95–3.02) |
2000–2009 | 271,978 (40%) | 1,707,398 | 159,751 (41%) | 47,098 (42%) | 2.21 (2.19–2.23) |
2010–2016 | 214,360 (31%) | 512,810 | 65,966 (17%) | 16,620 (15%) | 2.21 (2.18–2.24) |
Marital states | |||||
Married | 353,507 (52%) | 2,006,942 | 203,867 (52%) | 54,232 (48%) | 2.25 (2.23–2.27) |
Umarried | 282,973 (41%) | 1,496,235 | 165,341 (42%) | 51,172 (45%) | 2.96 (2.94–2.99) |
Unknown | 46,853 (7%) | 251,984 | 21,326 (5%) | 7768 (7%) | 2.05 (2.01–2.10) |
Radiotherapy | |||||
Yes | 111,543 (16%) | 845,788 | 58,543 (15%) | 16,751 (15%) | 2.45 (2.42–2.49) |
No/Unknown | 575,324 (84%) | 2,920,824 | 335,525 (86%) | 96,421 (85%) | 2.51 (2.50–2.53) |
Chemotherapy | |||||
Yes | 397,829 (58%) | 2,232,639 | 220,212(56%) | 50,599 (45%) | 2.49 (2.47–2.51) |
No/Unknown | 285,504 (42%) | 1,522,522 | 170,322(44%) | 62,573 (55%) | 2.51 (2.50–2.53) |
Diagnosis | |||||
ALL | 30,884 (5%) | 234,548 | 11,505 (3%) | 1283 (1%) | 5.25 (4.97–5.55) |
AML | 60,065 (9%) | 143,407 | 47,324 (12%) | 4745 (4%) | 5.13 (4.99–5.28) |
CLL | 76,594 (11%) | 472,786 | 42,383 (11%) | 18,636 (17%) | 1.87 (1.84–1.90) |
CML | 28,985 (4%) | 133,082 | 16,744 (4%) | 5054 (5%) | 3.27 (3.18–3.36) |
HL | 53,589 (8%) | 546,752 | 16,413 (4%) | 6183 (6%) | 3.81 (3.71–3.90) |
PCM | 101,140 (15%) | 349,177 | 71,692 (18%) | 17,280 (15%) | 2.79 (2.75–2.83) |
NHL | 311,250 (46%) | 1,780,946 | 170,080 (44%) | 56,270 (50%) | 2.40 (2.38–2.42) |
Other leukemias | 20,826 (3%) | 94,463 | 14,393 (4%) | 3721 (3%) | 3.05 (2.96–3.15) |
